高 potency 他汀与 CKD 患者骨质疏松减少但骨折风险增加相关:多中心回顾性研究
该回顾性队列研究利用 TriNetX 美国协作网络,纳入 CKD 3 或 4 期启动他汀治疗的成人,按高 potency 与低 potency 分组并经 1:1 倾向评分匹配。高 potency 他汀与 3–12 个月骨质疏松诊断减少 20.0% 及抗骨质疏松药物处方减少 24.9% 相关,且关联持续超过 12 个月;骨折风险在 3–12 个月无差异,但超过 12 个月增加。
要点
- 高 potency 他汀与 CKD 3–4 期患者骨质疏松诊断和抗骨质疏松药物处方减少相关。
- 骨折风险在 3–12 个月无差异,但超过 12 个月增加(HR 1.13)。
- 长期骨折风险增加可能反映诊断缺口导致骨脆性治疗不足。
核心结论
- 高 potency 他汀与 CKD 3 和 4 期患者较低的骨质疏松诊断率和较少的抗骨质疏松药物处方相关,但长期骨折风险增加。
研究设计与样本
- 多中心回顾性队列研究,使用 TriNetX 美国协作网络识别 CKD 3 或 4 期启动他汀治疗的成人,分为高 potency 组(阿托伐他汀 40-80 mg、瑞舒伐他汀 20-40 mg)和低 potency 组,经 1:1 倾向评分匹配后分析。
主要发现
- 共匹配 873,180 例患者,高 potency 他汀组在 3–12 个月骨质疏松诊断减少 20.0%(HR 0.80;95% CI 0.78-0.82),抗骨质疏松药物处方减少 24.9%(HR 0.75;95% CI 0.73-0.78),关联持续超过 12 个月。
- 骨折风险在 3–12 个月无差异(HR 0.99;95% CI 0.96-1.02),但超过 12 个月增加(HR 1.13;95% CI 1.11-1.15)。
关键数值与推荐
- 高 potency 他汀定义为阿托伐他汀 40-80 mg 或瑞舒伐他汀 20-40 mg。
- 主要结局包括新发骨质疏松诊断、启动抗骨质疏松药物和 incident fractures,评估时间点为 3–12 个月及超过 12 个月。
临床怎么用
- 对 CKD 3–4 期使用高 potency 他汀的患者,应关注长期骨折风险并主动监测骨健康。
- 骨质疏松诊断率降低可能反映诊断不足,需警惕骨脆性治疗不足的问题。
局限性
- 本研究为观察性设计,存在残余混杂可能。
- 需要前瞻性随机对照试验以骨特异性终点确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Chronic kidney disease patients face increased osteoporosis and fracture risk. High-potency statins were associated with lower osteoporosis incidence but also with higher long-term fracture incidence in this observational study. These findings highlight the need for tailored statin use and proactive fracture monitoring in CKD populations for optimal bone health management. PURPOSE: Chronic kidney disease (CKD) affects approximately 850 million people worldwide and is associated with increased risks of cardiovascular events and fractures. The differential effects of statin potency on bone health in CKD patients remain incompletely understood. METHODS: This retrospective cohort study used the TriNetX US Collaborative Network to identify adults with CKD stages 3 or 4 initiating statin therapy, categorized into high-potency (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) and low-potency groups. After 1:1 propensity score matching, three primary outcomes were evaluated: new osteoporosis diagnosis, anti-osteoporotic medication initiation, and incident fractures, assessed at 3-12 months and beyond 12 months. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox and competing risk regression models. RESULTS: Among 873,180 matched patients, high-potency statins were associated with a 20.0% reduction in osteoporosis diagnosis (HR 0.80; 95% CI 0.78-0.82) and 24.9% fewer anti-osteoporotic medication prescriptions (HR 0.75; 95% CI 0.73-0.78) during 3-12 months, with associations persisting beyond 12 months. Fracture risk did not differ at 3-12 months (HR 0.99; 95% CI 0.96-1.02); but increased beyond 12 months (HR 1.13; 95% CI 1.11-1.15). CONCLUSIONS: High-potency statins are associated with lower osteoporosis diagnosis rates and fewer anti-osteoporotic medication prescriptions in CKD stages 3 and 4. The increased long-term fracture risk may reflect a diagnostic gap wherein lower osteoporosis detection contributes to under-treatment of bone fragility. Prospective randomized controlled trials with bone-specific endpoints are warranted to confirm these findings.
引用
- Wu PH, Lin YT, Chen JC, et al. High-potency statins are associated with reduced osteoporosis but increased fracture risk in CKD patients: a multi-center retrospective study. Osteoporos Int. 2026. PMID: 41984206. doi:10.1007/s00198-026-08021-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。